This company listing is no longer active
NK8 Stock Overview
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NuVasive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.80 |
| 52 Week High | US$48.00 |
| 52 Week Low | US$33.80 |
| Beta | 1.07 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -12.38% |
| 3 Year Change | -14.02% |
| 5 Year Change | -37.81% |
| Change since IPO | 315.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| NK8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -3.0% | -0.4% |
| 1Y | -12.4% | -2.8% | 3.4% |
Return vs Industry: NK8 underperformed the German Medical Equipment industry which returned -10.7% over the past year.
Return vs Market: NK8 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| NK8 volatility | |
|---|---|
| NK8 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NK8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NK8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,000 | Chris Barry | www.nuvasive.com |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room.
NuVasive, Inc. Fundamentals Summary
| NK8 fundamental statistics | |
|---|---|
| Market cap | €1.94b |
| Earnings (TTM) | €26.41m |
| Revenue (TTM) | €1.14b |
73.3x
P/E Ratio1.7x
P/S RatioIs NK8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NK8 income statement (TTM) | |
|---|---|
| Revenue | US$1.23b |
| Cost of Revenue | US$347.50m |
| Gross Profit | US$878.73m |
| Other Expenses | US$850.28m |
| Earnings | US$28.45m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 71.66% |
| Net Profit Margin | 2.32% |
| Debt/Equity Ratio | 89.1% |
How did NK8 perform over the long term?
See historical performance and comparison